Neothetics Provides
Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
August 11, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update on its strategic and operational initiatives and reported financial results for the...
Neothetics to Provid
Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016
August 04, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide a business update and release its second quarter 2016 financial results before the...
Neothetics Reports F
Neothetics Reports First Quarter 2016 Financial Results
May 12, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today reported financial results and business progress for the first quarter 2016. First Quarter 2016 Highlights ...
Neothetics to Releas
Neothetics to Release First Quarter 2016 Financial Results
May 05, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that...
Neothetics to Presen
Neothetics to Present at the 15th Annual Needham Healthcare Conference
April 06, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, April 06, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan Knudson, Neothetics’ Chief Financial Officer, will present at the 15th Annual Needham...
Neothetics Provides
Neothetics Provides Update and Plan Forward for LIPO-202 Program
March 28, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, March 28, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided an update and plan forward for its LIPO-202 program. Neothetics plans to initiate a Phase 2 trial with...
Neothetics Announces
Neothetics Announces Leadership Change and Preliminary Update on LIPO-202
February 18, 2016 16:00 ET | Neothetics, Inc.
SAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced...
SENTÉ Appoints Laure
SENTÉ Appoints Laurent Combredet as President & Chief Executive Officer
February 09, 2016 12:00 ET | Sente, Inc.
SAN DIEGO, Feb. 09, 2016 (GLOBE NEWSWIRE) -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of...
SENTÉ Completes $5M
SENTÉ Completes $5M Capital Raise
February 08, 2016 12:00 ET | Sente, Inc.
SAN DIEGO, Feb. 08, 2016 (GLOBE NEWSWIRE) -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of...
Neothetics Initiates
Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat
April 13, 2015 08:00 ET | Neothetics, Inc.
SAN DIEGO, April 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the...